Scarica l'app Stockscreener
14.09
0.21%
-0.03
Dopo l'orario di chiusura:
14.02
-0.07
-0.50%
Precedente Chiudi:
$14.12
Aprire:
$14.22
Volume 24 ore:
275.99K
Relative Volume:
1.27
Capitalizzazione di mercato:
$474.37M
Reddito:
$99.99M
Utile/perdita netta:
$-21.47M
Rapporto P/E:
-21.36
EPS:
-0.6597
Flusso di cassa netto:
$-11.34M
1 W Prestazione:
+0.43%
1M Prestazione:
-6.38%
6M Prestazione:
+42.90%
1 anno Prestazione:
+35.09%
Intervallo 1D:
$13.98
$14.65
Intervallo di 1 settimana:
$13.53
$14.70
Portata 52W:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
14.09 | 474.37M | 99.99M | -21.47M | -11.34M | -0.6597 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com Nigeria
Published on: 2026-03-09 06:34:24 - baoquankhu1.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Outlook: Will NeuroPace Inc stock benefit from M AJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Rate Cut: Will NeuroPace Inc stock benefit from M AEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gains Recap: Is NeuroPace Inc a stock for growth or value investorsJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
NeuroPace to Present at the Leerink Global Healthcare Conference - Investing News Network
NeuroPace revenue up 24% to USD 26.6M in Q4 2025 - Medical Buyer
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - Sahm
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - TipRanks
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
Earnings call transcript: Neuropace beats Q4 2025 EPS forecast, stock dips - Investing.com Nigeria
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
NeuroPace reports $99.99M revenue, $(0.66) EPS in 10-K - TradingView
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
NeuroPace (NASDAQ:NPCE) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NeuroPace (NPCE) outlines RNS growth, trials and capital moves in 10-K - Stock Titan
NeuroPace Inc.: Fourth Quarter Earnings Overview - Bitget
Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Press Release: NeuroPace Reports First Quarter 2025 Financial Results - 富途牛牛
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% - Investing.com South Africa
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com Canada
NeuroPace Inc.: Q4 Earnings Snapshot - marketscreener.com
NeuroPace (NASDAQ: NPCE) posts 25% 2025 growth and sets 2026 revenue, margin guidance - Stock Titan
Earnings Summary: NeuroPace Q4 - Benzinga
NeuroPace, Inc. Reiterates Earnings Guidance for the first quarter and full year of 2026 - marketscreener.com
NeuroPace (NPCE) CEO covers RSU taxes through 1,126-share withholding - Stock Titan
NeuroPace Inc RNS System reduces seizure frequency in epilepsy patient Brian - Traders Union
NeuroPace (NPCE) CMO has 358 shares withheld for RSU tax - Stock Titan
Earnings Outlook For NeuroPace - Benzinga
NeuroPace Inc (NPCE) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
NPCE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):